Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lysostaphin - Bharat Biotechnologies

Drug Profile

Lysostaphin - Bharat Biotechnologies

Alternative Names: BBIL-5

Latest Information Update: 16 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bharat Biotech
  • Class Antibacterials; Metalloendopeptidases
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Staphylococcal infections

Most Recent Events

  • 14 Dec 2017 Bharat Biotechnologies completes a phase II/III trial in Staphylococcal infections in India (Topical) (CTRI2016-09-007277)
  • 06 Jun 2016 Phase-II/III clinical trials in Staphylococcal infections in India (Topical) (CTRI2016-09-007277)
  • 08 Sep 2015 Phase-II development for Staphylococcal infections is ongoing in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top